Dian Diagnostics Stock Hits Day Low of CNY 22.60 Amid Price Pressure

Dian Diagnostics Group Co. experienced significant activity on February 24, 2026, with the stock declining by 6.27% and reaching an intraday low of CNY 22.60. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, Dian Diagnostics has seen a decrease of 2.97%, while its monthly performance reflects a more substantial decline of 21.6%. Despite a notable annual gain of 49.9%, the stock's long-term trajectory appears concerning, with a three-year performance down by 15.92% and a five-year decline of 44.53%. The company's financial metrics indicate challenges, including a net profit decline of 93.58% in the first half of the year and a return on capital employed (ROCE) at a low of -6.05%. Additionally, the inventory turnover ratio stands at 4.91, marking a significant concern for operational efficiency. With a market capitalization of CNY 10,955 million, Dian Diagnostics operates within the pharmaceuticals and biotechnology sector, facing a complex landscape as it navigates these financial hurdles.